keyword
MENU ▼
Read by QxMD icon Read
search

Ovarian cancer treatment personalized

keyword
https://www.readbyqxmd.com/read/29786517/estrogen-receptor-%C3%AE-potential-target-for-therapy-in-adult-granulosa-cell-tumors
#1
Alessandra Ciucci, Gabriella Ferrandina, Floriana Mascilini, Flavia Filippetti, Giovanni Scambia, Gian Franco Zannoni, Daniela Gallo
OBJECTIVE: Adult granulosa cell tumor (AGCT) is a rare form of sex-cord stromal ovarian tumors. Due to their origin, AGCTs secrete estrogens, and thus, estrogen receptor (ER)-mediated signaling has been considered as a possible target for therapy. The aim of the present study was to get insights into estrogen receptor status and activity in AGCTs, as a strategy to provide molecular support for personalized hormonal treatments. METHODS: We evaluated by immunohistochemistry the expression of ERα, ERβ isoforms (i...
May 18, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29781548/multi-omics-in-high-grade-serous-ovarian-cancer-biomarkers-from-genome-to-the-immunome
#2
Cole Clifford, Natasha Vitkin, Sarah Nersesian, Gillian Reid-Schachter, Julie-Ann Francis, Madhuri Koti
Epithelial ovarian cancer (EOC) is a lethal gynaecological disease that imposes significant burden on health care and patient quality of life. High-grade serous carcinoma of the ovary (HGSC) is the most prevalent histological type of EOC. A vast majority of HGSC cases are diagnosed at late stages of the disease, limiting the opportunity for clinical intervention and resulting in a 10-year survival rate of <20%. Recent innovations in high-throughput molecular analysis of patient-derived specimens may address these clinical challenges by providing an enhanced understanding of the molecular aetiology of ovarian cancer, in addition to offering several opportunities for rational biomarker and targeted therapy discovery...
May 21, 2018: American Journal of Reproductive Immunology: AJRI
https://www.readbyqxmd.com/read/29727353/role-of-survivin-and-p53-expression-in-response-of-primary-culture-of-ovarian-cancer-cells-to-treatment-with-chemotherapeutic-agents
#3
Diwesh Chawla, Rajarshi Kar, Bindiya Gupta, Sumita Halder, Seema Garg, Mohit Mehndiratta, Neelam Wadhwa, Rachna Agarwal
BACKGROUND: Ovarian cancer is associated with a high relapse rate and is the fifth leading cause of cancer deaths in women. The genetic profile of a tumor is responsible for deciding response to chemotherapeutic agents. In this study, we investigate the relation between survivin and p53 expression and response to chemotherapeutic agents of primary cultures of ovarian cancer cells established from ascitic fluid. MATERIALS AND METHOD: Ascitic fluid and Dulbecco's modified Eagle medium was mixed in equal proportion in culture flasks and incubated to establish primary culture...
April 30, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29714649/personalized-therapy-based-on-sequential-molecular-analysis-leads-to-30-months-of-survival-in-a-patient-with-diffuse-unresectable-gastric-linitis-plastica
#4
Linda Mahjoubi, Fabiola Cecchi, Christophe Massard, Fabio Calabro, Anas Gazzah, Rastislav Bahleda, Philippe Jamme, Maximiliano Gelli, Diane Goere, Ludovic Lacroix, Julien Adam, Lukas Heukamp, Patrizia Trenta, Todd Hembrough, Jean-Charles Soria, Cora Sternberg, Michel Ducreux
INTRODUCTION: Diffuse gastric cancer is associated with poor prognosis. We report a patient with metastatic gastric linitis plastica harboring human epidermal growth factor receptor 2 ( HER2) activating mutation and HER2 amplification. CASE DESCRIPTION: The patient received 5-fluorouracil/folinic acid and oxaliplatin combined with trastuzumab/pertuzumab, resulting in disease control for 8 months. Second-line therapy with nivolumab and trastuzumab/pertuzumab was well-tolerated, with macroscopic peritoneal response...
March 1, 2018: Tumori
https://www.readbyqxmd.com/read/29696411/lymphatic-spread-of-ovarian-cancer-can-the-anatomical-and-pathological-knowledge-help-a-personalized-treatment
#5
EDITORIAL
Giovanni D Aletti
No abstract text is available yet for this article.
April 25, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29659826/association-between-ambient-air-pollution-and-pregnancy-rate-in-women-who-underwent-ivf
#6
S A Choe, Y B Jun, W S Lee, T K Yoon, S Y Kim
STUDY QUESTION: Are the concentrations of five criteria air pollutants associated with probabilities of biochemical pregnancy loss and intrauterine pregnancy in women? SUMMARY ANSWER: Increased concentrations of ambient particulate matter (PM10), nitrogen dioxide (NO2), carbon monoxide (CO) during controlled ovarian stimulation (COS) and after embryo transfer were associated with a decreased probability of intrauterine pregnancy. WHAT IS KNOWN ALREADY: Exposure to high ambient air pollution was suggested to be associated with low fertility and high early pregnancy loss in women...
April 5, 2018: Human Reproduction
https://www.readbyqxmd.com/read/29614442/the-role-of-genomic-profiling-in-adolescents-and-young-adults-ayas-with-advanced-cancer-participating-in-phase-i-clinical-trials
#7
Terri Patricia McVeigh, Raghav Sundar, Nikolaos Diamantis, Stan B Kaye, Udai Banerji, Juanita S Lopez, Johann de Bono, Winette T A van der Graaf, Angela J George
INTRODUCTION: Adolescents and young adults (AYAs) diagnosed with cancer between ages 15-39 years may harbour germline variants associated with cancer predisposition. Such variants represent putative therapeutic targets, as may somatic variants in the tumour. Germline and tumour molecular profiling is increasingly utilised to facilitate personalisation of cancer treatment in such individuals. AIM: Considering AYAs with advanced solid tumours managed in a specialist drug development unit (DDU), the aims of this study were to investigate the use and impact of: 1...
March 31, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29599910/developing-a-genetic-signature-to-predict-drug-response-in-ovarian-cancer
#8
Stephen Hyter, Jeff Hirst, Harsh Pathak, Ziyan Y Pessetto, Devin C Koestler, Rama Raghavan, Dong Pei, Andrew K Godwin
There is a lack of personalized treatment options for women with recurrent platinum-resistant ovarian cancer. Outside of bevacizumab and a group of poly ADP-ribose polymerase inhibitors, few options are available to women that relapse. We propose that efficacious drug combinations can be determined via molecular characterization of ovarian tumors along with pre-established pharmacogenomic profiles of repurposed compounds. To that end, we selectively performed multiple two-drug combination treatments in ovarian cancer cell lines that included reactive oxygen species inducers and HSP90 inhibitors...
March 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29599518/psychological-outcomes-and-surgical-decisions-after-genetic-testing-in-women-newly-diagnosed-with-breast-cancer-with-and-without-a-family-history
#9
Bettina Meiser, Veronica F Quinn, Gillian Mitchell, Kathy Tucker, Kaaren J Watts, Belinda Rahman, Michelle Peate, Christobel Saunders, Elizabeth Geelhoed, Margaret Gleeson, Kristine Barlow-Stewart, Michael Field, Marion Harris, Yoland C Antill, Rachel Susman, Michael T Bowen, Llew Mills, Judy Kirk
In patients with early breast cancer, personal and tumour characteristics other than family history are increasingly used to prompt genetic testing to guide women's cancer management (treatment-focused genetic testing, 'TFGT'). Women without a known strong family history of breast and/or ovarian may be more vulnerable to psychological sequelae arising from TFGT. We compared the impact of TFGT in women with (FH+) and without (FH-) a strong family history on psychological adjustment and surgical decisions. Women aged <50 years with high-risk features were offered TFGT before definitive breast cancer surgery and completed self-report questionnaires at four time points over 12 months...
March 30, 2018: European Journal of Human Genetics: EJHG
https://www.readbyqxmd.com/read/29569937/the-role-of-micrornas-and-nanoparticles-in-ovarian-cancer-a-review
#10
Leila Kafshdooz, Hojjat Pourfathi, Abolfazl Akbarzadeh, Taiebeh Kafshdooz, Zohre Razban, Roghayeh Sheervalilou, Naser Ebrahimi Sadr, Rovshan Khalilov, Siamak Saghfi, Taras Kavetskyy, Lala Mammadova, Masoud Mehrizadeh, Samaneh Ghasemali
MicroRNAs (miRNAs) have had a revolutionary impact on cancer research over the recent years. They emerge as important players in tumourigenesis, leading to a paradigm shift in oncology. Ovarian cancer is the leading cause of death among gynaecologic malignancies. Therefore, there is a strong need for prognostic and predictive markers for early diagnosis which helps optimize and personalize treatment. Asymptomatically, ovarian cancer is often diagnosed at advanced and incurable stages. Efficient targeting and sustained release of miRNAs/anti-miRNAs using nanoparticles conjugated with antibodies and/or peptides could reduce the required therapeutic dosage while minimizing systemic and cellular toxicity...
March 23, 2018: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/29420401/cancer-risk-after-midurethral-sling-surgery-using-polypropylene-mesh
#11
Daniel Altman, Rebecca G Rogers, Li Yin, Karl Tamussino, Weimin Ye, Cheryl B Iglesia
OBJECTIVE: To assess whether there is any association between the implantation of synthetic polypropylene mesh slings for the treatment of stress urinary incontinence (SUI) and risk of cancer. METHODS: We performed a nationwide cohort study based on the general female population in Sweden. All women entered the observational period as unexposed on January 1, 1997, and contributed person-time as unexposed unless they underwent a midurethral sling procedure for SUI, after which they contributed person-time as exposed until first occurrence of any cancer, death, emigration, or end of the observational period (December 31, 2009)...
March 2018: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29395152/controversies-in-the-management-of-ovarian-tumours-in-prepubertal-children-a-baps-and-uk-cclg-surgeons-cancer-group-national-survey
#12
Sarah Braungart, Ross J Craigie, Paul D Losty
BACKGROUND: No clear treatment and follow-up protocols have been established for prepubertal patients with ovarian tumours. The lack of adequate prospective data in the literature includes all aspects of their management. A significant number of children with ovarian masses present out of hours as a surgical emergency and are initially managed by paediatric surgeons without special interest in surgical oncology. Clear guidance on the management of such tumours is therefore fundamental...
December 27, 2017: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/29383036/development-of-a-personalized-therapeutic-strategy-for-erbb-gene-mutated-cancers
#13
Malgorzata Milewska, Mattia Cremona, Clare Morgan, John O'Shea, Aoife Carr, Sri H Velanki, Ann M Hopkins, Sinead Toomey, Stephen F Madden, Bryan T Hennessy, Alex J Eustace
Background: The application of genomic technologies to patient tumor samples identified groups of signaling pathways which acquire activating mutations. Some cancers are dependent on these mutations and the aberrant proteins resulting from these mutations can be targeted by novel drugs which can eradicate the cancer. Methods: We used www.cbioportal.org to determine the frequency of ERBB mutations in solid tumors. We then determined the sensitivity of a panel of cell lines to clinically available PI3K inhibitors...
2018: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29367611/genome-wide-association-study-of-paclitaxel-and-carboplatin-disposition-in-women-with-epithelial-ovarian-cancer
#14
Bo Gao, Yi Lu, Annemieke J M Nieuweboer, Hongmei Xu, Jonathan Beesley, Ingrid Boere, Anne-Joy M de Graan, Peter de Bruijn, Howard Gurney, Catherine J Kennedy, Yoke-Eng Chiew, Sharon E Johnatty, Philip Beale, Michelle Harrison, Craig Luccarini, Don Conroy, Ron H J Mathijssen, Paul R Harnett, Rosemary L Balleine, Georgia Chenevix-Trench, Stuart Macgregor, Anna de Fazio
Identifying single nucleotide polymorphisms (SNPs) that influence chemotherapy disposition may help to personalize cancer treatment and limit toxicity. Genome-wide approaches are unbiased, compared with candidate gene studies, but usually require large cohorts. As most chemotherapy is given cyclically multiple blood sampling is required to adequately define drug disposition, limiting patient recruitment. We found that carboplatin and paclitaxel disposition are stable phenotypes in ovarian cancer patients and tested a genome-wide association study (GWAS) design to identify SNPs associated with chemotherapy disposition...
January 24, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29336210/semi-supervised-identification-of-cancer-subgroups-using-survival-outcomes-and-overlapping-grouping-information
#15
Wei Wei, Zequn Sun, Willian A da Silveira, Zhenning Yu, Andrew Lawson, Gary Hardiman, Linda E Kelemen, Dongjun Chung
Identification of cancer patient subgroups using high throughput genomic data is of critical importance to clinicians and scientists because it can offer opportunities for more personalized treatment and overlapping treatments of cancers. In spite of tremendous efforts, this problem still remains challenging because of low reproducibility and instability of identified cancer subgroups and molecular features. In order to address this challenge, we developed Integrative Genomics Robust iDentification of cancer subgroups (InGRiD), a statistical approach that integrates information from biological pathway databases with high-throughput genomic data to improve the robustness for identification and interpretation of molecularly-defined subgroups of cancer patients...
January 1, 2018: Statistical Methods in Medical Research
https://www.readbyqxmd.com/read/29307198/inherited-pancreatic-cancer
#16
Fei Chen, Nicholas J Roberts, Alison P Klein
Pancreatic cancers arise through a series of genetic events both inherited and acquired. Inherited genetic changes, both high penetrance and low penetrance, are an important component of pancreatic cancer risk, and may be used to characterize populations who will benefit from early detection. Furthermore, pancreatic cancer patients with inherited mutations may be particularly sensitive to certain targeted agents, providing an opportunity to personalized treatment. Family history of pancreatic cancer is one of the strongest risk factors for the disease, and is associated with an increased risk of caners at other sites, including but not limited to breast, ovarian and colorectal cancer...
December 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29277822/bevacizumab-added-to-moderate-dose-chemotherapy-for-refractory-uterine-cancer
#17
Howard W Bruckner, Daniel Gurell, Azriel Hirschfeld
BACKGROUND/AIM: Bevacizumab (bev), when added to a moderate dose combination of previously failed cytotoxins, as a third- and fourth-line therapy for refractory gastric, cholangiocarcinoma, and ovarian cancers, produced high-quality responses. The regimen was based on preclinical models designed in order to simultaneously partner both bev and each of the cytotoxins with 4-5 synergistic drugs. PATIENTS AND METHODS: Eligible patients (n=9) had high-grade endometrial tumors and had failed standard chemotherapy...
January 2018: Anticancer Research
https://www.readbyqxmd.com/read/29250506/development-of-second-primary-cancer-in-korean-breast-cancer-survivors
#18
Hong Kyu Jung, Suyeon Park, Nam Won Kim, Jong Eun Lee, Zisun Kim, Sun Wook Han, Sung Mo Hur, Sung Young Kim, Cheol Wan Lim, Min Hyuk Lee, Jihyoun Lee
Purpose: Breast cancer survivors have slightly increased the risk of second primary cancers. Breast, colon, uterine, and ovarian cancers are common secondary cancers in breast cancer survivors. In this study, we assessed the development of second primary cancers of breast cancer survivors in Korea. Methods: Medical records of patients with breast cancer in 3 tertiary medical institutions were reviewed retrospectively. We evaluated secondary malignancy diagnosed at least 2 months after the breast cancer diagnosis...
December 2017: Annals of Surgical Treatment and Research
https://www.readbyqxmd.com/read/29249039/advances-in-ovarian-cancer-therapy
#19
REVIEW
Alexander J Cortez, Patrycja Tudrej, Katarzyna A Kujawa, Katarzyna M Lisowska
Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials...
January 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29232474/is-intraperitoneal-chemotherapy-still-an-acceptable-option-in-primary-adjuvant-chemotherapy-for-advanced-ovarian-cancer
#20
B J Monk, J K Chan
The role of intraperitoneal (i.p.) chemotherapy in treating newly diagnosed advanced epithelial ovarian cancer (EOC) has been the subject of controversy for almost three decades. Three large intergroup phase III trials (GOG 104, 114, 172) have demonstrated a survival benefit associated with i.p. over intravenous (i.v.) therapy in advanced, low-volume EOC. Despite the positive clinical trial results and a subsequent National Cancer Institute alert in 2006, i.p. treatment has not been widely accepted as the standard of care in the United States and is infrequently used in Europe...
November 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
24373
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"